3-MeO-PCP
3-methoxyphencyclidine
Standing risks
| Risk | Recorded values | Confidence | Article section |
|---|---|---|---|
| High overdose risk, use caution |
| medium | View in article: High overdose risk, use caution |
Lethal interactions
| Combination | Type | Severity | Mechanisms | Confidence |
|---|---|---|---|---|
| Benzodiazepines, Barbiturates | Drug class | lethal | 2 | high |
| GHB, Baclofen | Drug class | lethal | 2 | high |
| GHB, GBL | Drug class | lethal | 2 | medium |
| Ibogaine | Drug class | lethal | 3 | medium |
| Local anesthetics | Drug class | lethal | 4 | medium |
Dangerous interactions
37 dangerous interactions recorded for this substance.
See the full interactions tableContraindications
| Condition | Severity | Note |
|---|---|---|
| Cardiovascular | ||
| cardiac arrhythmia | absolute | Pre-existing arrhythmias may be exacerbated by cardiovascular effects and predicted QT-prolongation. |
| Respiratory | ||
| respiratory disease | relative | Pre-existing respiratory conditions may lower the threshold for respiratory complications. |
| Psychiatric | ||
| bipolar disorder | absolute | Mania-like disinhibition, grandiosity, and agitation are documented. Bipolar disorder predisposes to triggered manic or psychotic episodes. |
| Hepatic | ||
| hepatic impairment | relative | Hepatic impairment may prolong exposure and increase peak plasma concentrations. |
| Pregnancy & Breastfeeding | ||
| pregnancy and breastfeeding | absolute | pregnancy, breastfeeding Absolute contraindication inferred from NMDA antagonist class. No substance-specific reproductive data available. |
| Other | ||
| concurrent CYP2D6 inhibitor use | relative | CYP2D6 inhibition may increase effective dose exposure. Clinically significant interaction not confirmed but mechanistically plausible. |